Should I stay, or should I go? – How fund dynamics influence venture capital exit decisions

Learning to let go: Social influence, learning, and the abandonment of corporate venture capital practices

This study examines the abandonment of organizational practices. We argue that firm choices in implementing practices affect how firms experience a practice and their subsequent likelihood of abandonment. We focus on utilization of the practice and staffing, i.e. career backgrounds of managers, as two important implementation choices that firms make. The findings demonstrate that practice utili...

Network Ties, Reputation, and the Financing of New Ventures

Explaining how entrepreneurs overcome information asymmetry between themselves and potential investors to obtain financing is an important issue for entrepreneurship research. Our premise is that economic explanations for venture finance, which do not consider how social ties influence this process, are undersocialized and incomplete. However, we also argue that organization theoretic arguments...

A pecking order of venture capital exits - What determines the optimal exit channel for venture capital backed ventures?

I develop a model of exits from venture capital backed companies based on moral hazard. The focus is on two alternatives: a trade sale and an IPO. The alternatives differ in their governance structure. The model shows that highly profitable companies that need few oversight will go public, while less profitable companies that require more control will be sold. This suggests that the common noti...

Should I stay or should I go? Condition- and status-dependent courtship decisions in the scorpionfly Panorpa cognata

I-25: Gamete Cryopreservation for Cancer Patients,Ethical Considerations

Cancer patients often receive gonadotoxic treatments, such as radiation or certain chemotherapies. The doses and regimens used for treatment vary in different individuals and cancers. Recent progress has improved the survival rates of patients with cancer, often using highly aggressive therapies and combinations. This results in growing numbers of cancer survivors, some of whom will be sterile ...